NCT00377936 - EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas | Biotech Hunter

Enrollment

212

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

October 31, 2008

Conditions

AdenocarcinomaMetastasisPancreas Neoplasms

Interventions

DRUG

Gemcitabine alone

Gemcitabine monotherapy 1000 mg/m2 weekly

DRUG

EndoTAG-1 and Gemcitabine

EndoTAG-1 11 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly

DRUG

EndoTAG-1 and Gemcitabine

EndoTAG-1 22 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly

DRUG

EndoTAG-1 and Gemcitabine

EndoTAG-1 44 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly

Trial Locations (3)

Prague

Budapest

Kiev